The directors report indicates that the company is pretty much holding back on spending money on Oraline 4 or Oraline 6 which is good IMO given the results of testing last June. The new shareholders who received 82m shares at 1c will surely be getting keen to see that their investment was a smart one now that the biotech sector is picking up. Sadly the depth does not make the stock look attractive but that could change in an instant. With the half yearly report out of the way now will directors be bold enough to buy more shares on market?
We await an update on the asthma trial and news of acquisitions.
SBN Price at posting:
0.8¢ Sentiment: None Disclosure: Held
